Insmed Incorporated beat EPS estimates 31% of the time across 16 reported quarters (5 beats, 11 misses), averaging -11.4% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.69 | $-0.52 | +24.6% | Beat | |
| Q1 FY26 | $-0.90 | $-0.76 | +15.6% | Beat | |
| Q3 FY25 | $-1.32 | $-1.75 | -32.6% | Miss | |
| Q2 FY25 | $-1.30 | $-1.70 | -30.8% | Miss | |
| Q1 FY25 | $-1.36 | $-1.42 | -4.4% | Miss | |
| Q4 FY24 | $-1.15 | $-1.32 | -14.8% | Miss | |
| Q3 FY24 | $-1.19 | $-1.27 | -6.7% | Miss | |
| Q2 FY24 | $-1.22 | $-1.94 | -59.0% | Miss | |
| Q1 FY24 | $-1.22 | $-1.06 | +13.1% | Beat | |
| Q4 FY23 | $-1.13 | $-1.28 | -13.3% | Miss | |
| Q3 FY23 | $-1.06 | $-1.10 | -3.8% | Miss | |
| Q2 FY23 | $-1.10 | $-1.78 | -61.8% | Miss |
Back to INSM overview · INSM holders · INSM KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.